Combined lowering of low grade systemic inflammation and insulin resistance in metabolic syndrome patients treated with Ginkgo biloba

G. Siegel; E. Ermilov; O. Knes; M. Rodríguez

doi:10.1016/j.atherosclerosis.2014.10.023

Combined lowering of low grade systemic inflammation and insulin resistance in metabolic syndrome patients treated with Ginkgo biloba

G. Siegel, E. Ermilov, O. Knes, M. Rodríguez

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

In a clinical pilot study with eleven metabolic syndrome patients, a simultaneous decrease in hs-CRP from 8.85±4.09 to 4.92±2.51mg/L (-44.4%) (p<0.0436) and HOMA-IR from 3.07±0.63 to 2.60±0.51. mU/L×mg/dL (-15.3%) (p<0.0120) as well as a beneficial change of arteriosclerotic, inflammatory and oxidative stress biomarkers were detected after 2-month treatment with Ginkgo biloba. Furthermore, both IL-6 (-12.9%, p<0.0407) and nanoplaque formation (-14.3%, p<0.0077) were additionally reduced. According to a large clinical trial elucidating the importance of insulin resistance and low-grade systemic inflammation for cardiovascular disease and overall mortality risk, these data might indicate a CVD/total mortality risk reduction.

Original language	English
Pages (from-to)	584-588
Number of pages	5
Journal	Atherosclerosis
Volume	237
Issue number	2
DOIs	https://doi.org/10.1016/j.atherosclerosis.2014.10.023
State	Published - Dec 1 2014
Externally published	Yes

Keywords

CVD/total mortality risk
Ginkgo biloba
High-sensitivity C-reactive protein (hs-CRP)
Homeostasis model assessment of insulin resistance (HOMA-IR)
Metabolic syndrome patients

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.atherosclerosis.2014.10.023

Cite this

@article{2e0598a45c3c440a953d81690158e771,

title = "Combined lowering of low grade systemic inflammation and insulin resistance in metabolic syndrome patients treated with Ginkgo biloba",

abstract = "In a clinical pilot study with eleven metabolic syndrome patients, a simultaneous decrease in hs-CRP from 8.85±4.09 to 4.92±2.51mg/L (-44.4%) (p<0.0436) and HOMA-IR from 3.07±0.63 to 2.60±0.51. mU/L×mg/dL (-15.3%) (p<0.0120) as well as a beneficial change of arteriosclerotic, inflammatory and oxidative stress biomarkers were detected after 2-month treatment with Ginkgo biloba. Furthermore, both IL-6 (-12.9%, p<0.0407) and nanoplaque formation (-14.3%, p<0.0077) were additionally reduced. According to a large clinical trial elucidating the importance of insulin resistance and low-grade systemic inflammation for cardiovascular disease and overall mortality risk, these data might indicate a CVD/total mortality risk reduction.",

keywords = "CVD/total mortality risk, Ginkgo biloba, High-sensitivity C-reactive protein (hs-CRP), Homeostasis model assessment of insulin resistance (HOMA-IR), Metabolic syndrome patients",

author = "G. Siegel and E. Ermilov and O. Knes and M. Rodr{\'i}guez",

note = "Publisher Copyright: {\textcopyright} 2014 Elsevier Ireland Ltd.",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.atherosclerosis.2014.10.023",

language = "English",

volume = "237",

pages = "584--588",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Combined lowering of low grade systemic inflammation and insulin resistance in metabolic syndrome patients treated with Ginkgo biloba

AU - Siegel, G.

AU - Ermilov, E.

AU - Knes, O.

AU - Rodríguez, M.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - In a clinical pilot study with eleven metabolic syndrome patients, a simultaneous decrease in hs-CRP from 8.85±4.09 to 4.92±2.51mg/L (-44.4%) (p<0.0436) and HOMA-IR from 3.07±0.63 to 2.60±0.51. mU/L×mg/dL (-15.3%) (p<0.0120) as well as a beneficial change of arteriosclerotic, inflammatory and oxidative stress biomarkers were detected after 2-month treatment with Ginkgo biloba. Furthermore, both IL-6 (-12.9%, p<0.0407) and nanoplaque formation (-14.3%, p<0.0077) were additionally reduced. According to a large clinical trial elucidating the importance of insulin resistance and low-grade systemic inflammation for cardiovascular disease and overall mortality risk, these data might indicate a CVD/total mortality risk reduction.

AB - In a clinical pilot study with eleven metabolic syndrome patients, a simultaneous decrease in hs-CRP from 8.85±4.09 to 4.92±2.51mg/L (-44.4%) (p<0.0436) and HOMA-IR from 3.07±0.63 to 2.60±0.51. mU/L×mg/dL (-15.3%) (p<0.0120) as well as a beneficial change of arteriosclerotic, inflammatory and oxidative stress biomarkers were detected after 2-month treatment with Ginkgo biloba. Furthermore, both IL-6 (-12.9%, p<0.0407) and nanoplaque formation (-14.3%, p<0.0077) were additionally reduced. According to a large clinical trial elucidating the importance of insulin resistance and low-grade systemic inflammation for cardiovascular disease and overall mortality risk, these data might indicate a CVD/total mortality risk reduction.

KW - CVD/total mortality risk

KW - Ginkgo biloba

KW - High-sensitivity C-reactive protein (hs-CRP)

KW - Homeostasis model assessment of insulin resistance (HOMA-IR)

KW - Metabolic syndrome patients

UR - http://www.scopus.com/inward/record.url?scp=84910072084&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2014.10.023

DO - 10.1016/j.atherosclerosis.2014.10.023

M3 - Article

AN - SCOPUS:84910072084

SN - 0021-9150

VL - 237

SP - 584

EP - 588

JO - Atherosclerosis

JF - Atherosclerosis

IS - 2

ER -

Combined lowering of low grade systemic inflammation and insulin resistance in metabolic syndrome patients treated with Ginkgo biloba

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this